Ash Access Technology, Inc. Completes Patient Enrollment in AZEPTIC Trial for Zuragen(R)

LAFAYETTE, IN--(Marketwire - January 24, 2008) - Ash Access Technology, Inc., a privately held specialty pharmaceutical and medical device company focused on vascular access innovations, announced today that patient enrollment in the AZEPTIC Trial for its flagship antimicrobial / antithrombotic therapy Zuragen® was completed in December of last year. The pivotal trial is a multi-centered, randomized study evaluating the efficacy and safety of Zuragen® for the prevention and treatment of catheter-related bloodstream infection (CRBSI) in end-stage renal disease patients requiring the use of a tunneled central venous catheter for hemodialysis compared to heparin, the current standard of care. The trial enrolled 415 patients at 25 dialysis facilities across the United States. Portions of the AZEPTIC Trial were financed through grants awarded by the National Institutes of Health (NIH) and the Indiana 21st Century Research and Technology Fund.